As a minimally invasive technology for detecting signs of cancer and other diseases, the liquid biopsy can sidestep stressful, costly surgical procedures. QIAGEN’s liquid biopsy solutions enable you to sensitively, specifically and quickly analyze circulating free nucleic acids (cfDNA), exosomes and circulating tumor cells (CTCs) from blood and other biofluids. This means you can find and study elusive low-abundance DNA fragments, evaluate valuable biomarkers from cellular vesicles, or even analyze a whole genome or transcriptome from a single tumor cell.
About the speaker
Constanze Kindler, Associate Director Global Product Management
Date of recording:Monday, March 8, 2021
Duration:60 minutes
Immune Response
Liquid Biopsy